The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer.
 
Scott Joseph Antonia
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck
 
Sang-We Kim
No Relationships to Disclose
 
Alexander I. Spira
Honoraria - Novartis; Roche
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Clovis Oncology; MedImmune; Roche
Expert Testimony - Novartis
Travel, Accommodations, Expenses - Roche
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Research Funding - AstraZeneca
 
Sai-Hong Ignatius Ou
Honoraria - Pfizer; Roche Pharma AG
Consulting or Advisory Role - Pfizer; Roche/Genentech
Speakers' Bureau - Boehringer Ingelheim; Genentech
Research Funding - ARIAD (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); Roche Pharma AG (Inst)
 
Neda Stjepanovic
No Relationships to Disclose
 
Angela Fasolo
No Relationships to Disclose
 
Dirk Jäger
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Definiens; Roche/Genentech
 
Patrick Alexander Ott
Consulting or Advisory Role - Alexion Pharmaceuticals; Amgen; Bristol-Myers Squibb
Research Funding - ARMO BioSciences; AstraZeneca; Bristol-Myers Squibb; Merck
 
Zev A. Wainberg
Consulting or Advisory Role - Sirtex Medical; Taiho Pharmaceutical
Speakers' Bureau - Genentech
Research Funding - Biomarin (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Genentech; Lilly
 
Heather A. Wakelee
Honoraria - ACEA Biosciences; Biocon; Helsinn Therapeutics; Peregrine Pharmaceuticals; Pfizer
Consulting or Advisory Role - ACEA Biosciences; Helsinn Therapeutics; Peregrine Pharmaceuticals; Pfizer
Research Funding - Agennix (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - ACEA Biosciences; Clovis Oncology; Novartis; Pfizer
 
Jonathan Wade Goldman
Honoraria - Clovis Oncology; Genentech
Research Funding - ArQule; Astex Pharmaceuticals; AstraZeneca/MedImmune; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Lilly; Synta
 
John Kurland
Employment - AstraZeneca/MedImmune; Bristol-Myers Squibb
Stock and Other Ownership Interests - AstraZeneca/MedImmune; Bristol-Myers Squibb
 
Marlon C. Rebelatto
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca
Patents, Royalties, Other Intellectual Property - AstraZeneca/MedImmune
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
 
Wenliang Yao
Employment - MedImmune
Stock and Other Ownership Interests - MedImmune
 
Ashok Kumar Gupta
Employment - MedImmune
 
John A. Blake-Haskins
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
 
Neil Howard Segal
Honoraria - MedImmune
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Imugene; Kyocera; Macrogenics; Pfizer; Roche/Genentech
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Pfizer; Roche/Genentech